Dupilumab therapy for atopic dermatitis and aneurysmal subarachnoid hemorrhage: A case report and literature review

Article information

Korean J Cerebrovasc Surg. 2026;.jcen.2026.E2025.12.004
Publication date (electronic) : 2026 July 30
doi : https://doi.org/10.7461/jcen.2026.E2025.12.004
1Department of Neurosurgery, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, Korea
2Department of Neurology, Konkuk University Medical Center, Seoul, Korea
3Department of Neurosurgery, Hallym University College of Medicine, Chuncheon, Korea
4Department of Population and Quantitative Health Sciences, UMass Chan Medical School, Worcester, MA, USA
Correspondence to Jong-Kook Rhim Department of Neurosurgery, Jeju National University College of Medicine, Aran 13gil 15 (Ara-1 Dong) Jeju-si, Jeju Self-Governing Province, 63241, Korea Tel +82-64-717-2106 Fax +82-64-717-1782 E-mail nsrhim@jejunu.ac.kr
Received 2025 December 4; Revised 2026 March 3; Accepted 2026 June 29.

Abstract

Dupilumab is a human IgG4 monoclonal antibody that inhibits IL-4 and IL-13 signaling through IL-4Rα, thereby reducing Th2-mediated inflammation. Although it has demonstrated significant efficacy in the treatment of atopic dermatitis, its long-term vascular safety profile remains incompletely understood. We report a case of a 27-year-old male who developed sudden headache after physical exertion while receiving Dupilumab therapy for two years. Brain computed tomography revealed subarachnoid hemorrhage, and angiography demonstrated a ruptured dissecting aneurysm in the distal posterior cerebral artery. The patient underwent successful stent-assisted coil embolization, and follow-up imaging confirmed complete occlusion without neurological deficits. Dupilumab therapy was discontinued after the procedure. Although Dupilumab effectively suppresses allergic inflammation, chronic inhibition of the anti-inflammatory cytokines IL-4 and IL-13 signaling may theoretically influence vascular homeostasis through alterations in inflammatory pathways. Such mechanisms could potentially affect endothelial stability or thrombo-inflammatory balance. Given the inherent limitations of a single case report, a causal relationship cannot be established. However, this case raises the possibility of an association between prolonged Dupilumab therapy and cerebrovascular vulnerability, highlighting the need for further investigation into the vascular effects of long-term cytokine inhibition.

INTRODUCTION

Stroke in young adults exhibits distinct clinical characteristics compared with those observed in middle-aged and elderly populations. In particular, the association with traditional vascular risk factors such as hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, and smoking tends to be relatively low. In contrast, causes that are rare in older individuals are more frequently observed in younger adults, and the etiology of stroke in this population is markedly heterogeneous. Moreover, in many cases, the precise cause remains unidentified [10].

Posterior cerebral artery (PCA) aneurysms are relatively rare, comprising approximately 0.7% to 2.3% of all intracranial aneurysms [13] and roughly 7% of those located in the posterior circulation [6]. The majority of PCA aneurysms (approximately 90%) arise in the P1 and P2 segments, while aneurysms involving the more distal P3 and P4 segments are uncommon [8]. These distal PCA aneurysms are particularly rare compared with proximal PCA aneurysms and have distinct clinical characteristics that warrant careful consideration.

Comprehensive analyses of posterior cerebral artery aneurysms have demonstrated that P3 segment aneurysms, particularly those with fusiform morphology, are rare, comprising only about 2% to 3 % of all posterior cerebral artery aneurysms. Despite their rarity, several studies have suggested that distal PCA aneurysms exhibit a relatively high propensity for rupture. Reported rupture rates in distal lesions reach up to 75% to 100%, which markedly exceeds the approximately 27% rupture rate reported for proximal PCA aneurysms [3,4]. These findings highlight the clinical significance of distal PCA aneurysms and emphasize the importance of recognizing and reporting such cases.

The disproportionately high rupture rate observed in distal PCA aneurysms remains poorly understood. One possible explanation is their location in low-flow regions with inherently thinner vessel walls, which may predispose them to rupture [5].

In this context, we report a case of aneurysmal subarachnoid hemorrhage caused by rupture of a fusiform aneurysm in the distal P3 segment of the posterior cerebral artery in a young adult receiving long-term Dupilumab therapy for atopic dermatitis. Given the inherent limitations of a single case report, this report does not aim to establish Dupilumab as a causal risk factor but rather to describe a possible association and explore potential mechanisms that may warrant further investigation.

CASE DESCRIPTION

A 27-year-old man presented to the emergency department with a sudden onset of headache after physical exertion at home. He was ambulatory upon arrival and did not report any additional symptoms. Neurological examination revealed no focal deficits. The patient had a known history of atopic dermatitis and had been receiving Dupilumab injections every two weeks since August 30, 2022. His most recent 300 mg subcutaneous injection was administered on July 30, 2024, approximately two weeks prior to the onset of symptoms, with a total of 48 doses administered before presentation.

Brain computed tomography (CT) performed in the emergency department revealed a subarachnoid hemorrhage (SAH) (Fig. 1A). Subsequent transfemoral cerebral angiography (TFCA) demonstrated a ruptured aneurysm located in the right distal posterior cerebral artery (PCA) (Fig. 1B). The aneurysm appeared irregular and fusiform in morphology, and was located in the distal P3 segment of the parieto-occipital branch of the posterior cerebral artery (Fig. 1B). Angiographic findings demonstrated tapered stenosis with focal dilatation, producing a pearland-string appearance suggestive of a dissecting aneurysm (Fig. 1B). Emergent stent-assisted coil embolization was performed (Fig. 1C). The final angiogram confirmed complete occlusion of the aneurysm without residual filling, and the procedure was completed without any complications (Fig. 1D).

Fig. 1.

(A) Initial brain computed tomography presented diffuse subarachnoid hemorrhage. (B) The fusiform aneurysm was seen on distal P3 at parieto-occipital artery. (C) Coil embolization was performed with stent assistance and postprocedural angiogram showed the complete occlusion without any complication. (D) No abnormality was shown in the follow up angiogram.

Follow-up TFCA was performed to evaluate the status of the treated dissecting aneurysm, and no abnormal findings were observed. Additional vessel wall magnetic resonance imaging (MRI) also showed no abnormalities. The patient remained neurologically stable without clinical deterioration and was discharged on postoperative day 13. At the one-month outpatient follow-up, the patient reported no neurological symptoms. Dupilumab therapy was discontinued after the procedure as part of the clinical management plan.

DISCUSSION

Previous studies have suggested a potential association between atopic dermatitis (AD) and ischemic stroke in adults, with in vitro research indicating that impaired fibrinolysis may contribute to increased platelet activation and fibrin clot formation [5,7,11]. However, atopic dermatitis has not been previously reported as a causative factor for hemorrhagic stroke in young adults.

In the present case, a subarachnoid hemorrhage occurred due to rupture of a fusiform aneurysm in the distal P3 segment of the posterior cerebral artery in a young patient without conventional vascular risk factors. Although aggressive physical exertion may have contributed to arterial dissection, the possible influence of long-term Dupilumab therapy cannot be excluded. Importantly, a causal relationship between Dupilumab therapy and aneurysmal rupture cannot be established based on a single case report. Rather, this case suggests only a possible temporal association that warrants further investigation.

To better contextualize the present case, we reviewed previously reported cerebrovascular events temporally associated with Dupilumab therapy and summarized them in Table 1. The available literature suggests that such events remain extremely rare and have predominantly involved ischemic mechanisms. In contrast, hemorrhagic cerebrovascular events associated with Dupilumab have not been clearly documented, making the present case particularly noteworthy.

Reported cerebrovascular events temporally associated with Dupilumab therapy

Alternative explanations should also be considered. The aneurysm may have represented a preexisting vascular lesion that ruptured spontaneously, which is a recognized mechanism in distal PCA aneurysms. In addition, underlying inflammatory conditions such as atopic dermatitis itself may contribute to vascular dysfunction through chronic immune activation and systemic inflammatory reponses.

To explore potential mechanisms underlying this possible association, several hypotheses may be considered. The first hypothesis involves vascular endothelial dysfunction [5]. As previously mentioned, interleukin-4 (IL-4) and interleukin-13 (IL-13) are key cytokines in the Th2-mediated immune responses and are primarily associated with allergic inflammation. These cytokines have also been reported to exert regulatory and anti-inflammatory effects on vascular endothelial cells [9].

IL-4 and IL-13 interact with pro-inflammatory cytokines such as IL-1β and TNF-α to modulate the immune response. When these signaling pathways are inhibited by Dupilumab, the regulatory effects of IL-4 and IL-13 on endothelial cells may theoretically be reduced. This could potentially result in endothelial dysfunction through increased activity of pro-inflammatory mediators such as TNF-α.

Previous studies have shown that IL-4 suppresses the secretion of IL-1β and TNF-α in human monocytes, suggesting an important role of IL-4 in immune regulation and inflammatory control. Therefore, inhibition of IL-4 and IL-13 signaling may theoretically lead to increased vascular permeability and potential weakening of vascular structures [12].

The second hypothesis involves increased vascular inflammation [5]. Inhibition of IL-4 and IL-13 signaling may promote M1 macrophage activation, thereby favoring a pro-inflammatory immune response. Although this mechanism has not been directly demonstrated in cerebrovascular disease, it could theoretically contribute to vascular wall vulnerability or exacerbate pre-existing vascular abnormalities.

Inflammation is known to play a central pathogenic role in the development of cardiovascular and cerebrovascular disease [1]. Anti-inflammatory cytokines such as IL-4 and IL-13 suppress the release of histamine and other inflammatory mediators and reduce the production of pro-inflammatory cytokines including IL-1β and TNF-α.

TNF-α and IL-1β are also key inflammatory mediators involved in secondary brain injury following hemorrhagic stroke. Their levels have been shown to increase significantly after the onset of hemorrhage [14]. Elevated TNF-α may exacerbate brain injury by promoting cerebral edema and neurological dysfunction [14], while increased IL-1β has been associated with blood-brain barrier (BBB) disruption and severe cerebral edema.

The third hypothesis involves a potential imbalance between thrombosis and hemostasis [5]. IL-4 and IL-13 have been reported to contribute to the maintenance of anticoagulant properties in vascular endothelium. Therefore, inhibition of these cytokines may theoretically influence thrombo-inflammatory pathways that could affect vascular stability.

In addition to these inflammatory mechanisms, chronic inhibition of IL-4 and IL-13 signaling may also influence vascular remodeling and structural integrity of the arterial wall [1,7]. IL-4 and IL-13 have been implicated in tissue repair processes and extracellular matrix regulation [1,7]. Therefore, prolonged blockade of these cytokines by Dupilumab could theoretically impair vascular repair mechanisms. Such alterations may affect extracellular matrix homeostasis, potentially leading to structural changes in the vascular wall, including thinning of the internal elastic lamina or alterations in collagen synthesis. These changes could contribute to increased susceptibility of the arterial wall to mechanical stress and may predispose vulnerable vessels to aneurysmal progression or rupture. Although direct evidence for this mechanism in cerebrovascular disease remains limited, such a hypothesis may provide a biologically plausible explanation for the potential interaction between chronic IL-4/IL-13 inhibition and vascular wall vulnerability.

In the present patient, laboratory evaluation for systemic vasculitis was performed to assess the possibility of an underlying systemic vascular disorder, and all results were within normal ranges. Although these findings do not completely exclude subtle vascular vulnerability, they reduce the likelihood of an underlying systemic vasculitic process contributing to the aneurysmal rupture. Taken together, it is possible that aggressive physical exertion may have acted as a mechanical trigger for arterial injury, while long-term Dupilumab therapy may have influenced vascular homeostasis, potentially contributing to vascular wall vulnerability.

Taken together, these mechanisms remain speculative and require further experimental and clinical validation. The present case does not establish Dupilumab as a definitive risk factor for aneurysmal subarachnoid hemorrhage. Instead, it highlights a possible association between prolonged Dupilumab therapy and cerebrovascular vulnerability in a young patient. Further studies are needed to better understand the vascular effects of long-term IL-4 and IL-13 signaling inhibition and to determine whether any causal relationship exists.

CONCLUSIONS

This case describes aneurysmal subarachnoid hemorrhage caused by rupture of a distal posterior cerebral artery aneurysm in a young adult receiving long-term Dupilumab therapy for atopic dermatitis. Given the inherent limitations of a single case report, a causal relationship between Dupilumab therapy and hemorrhagic cerebrovascular events cannot be established. However, this case raises the possibility of a potential association between prolonged Dupilumab exposure and cerebrovascular vulnerability. Further studies are required to better understand the vascular safety profile of long-term Dupilumab therapy and to clarify whether any meaningful relationship with cerebrovascular events exists.

Notes

ACKNOWLEDGMENTS

This study was supported by the 2025 Education, Research, and Student Guidance Grant funded by Jeju National University.

Informed consent

The patient provided written informed consent for participation and publication.

Disclosures

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

References

1. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nature Reviews Drug Discovery 2022;Jan. 21(1):21–40.
2. Feng H, Liu Y, Dong X, Zhou L. Dupilumab-induced systemic hypoperfusion in an elderly patient: A case report. J Inflamm Res 2025;Dec. 18:18323–9.
3. Goehre F, Jahromi BR, Hernesniemi J, Elsharkawy A, Kivisaari R, Vonund zu Fraunberg M, et al. Characteristics of posterior cerebral artery aneurysms: An angiographic analysis of 93 aneurysms in 81 patients. Neurosurgery 2014;Aug. 75(2):134–44.
4. Goehre F, Jahromi BR, Lehecka M, Lehto H, Kivisaari R, Andrade-Barazarte H, et al. Posterior cerebral artery aneurysms: Treatment and outcome analysis in 121 patients. World Neurosurgery 2016;Aug. 92:521–32.
5. Iwase R, Ishiguro T, Fujita K, Ishibashi S, Yokota T. Dupilumab for atopic dermatitis, a possible risk factor of juvenile ischemic stroke: A case report. Journal of Stroke and Cerebrovascular Disease 2020;Jun. 29(6):104763.
6. Li XY, Li CH, Wang JW, Liu JF, Li H, Gao BL. Endovascular management of cerebral aneurysms of the posterior cerebral artery. Front Neurol 2021;Oct. 12:700516.
7. Nastałek M, Wojas-Pelc A, Undas A. Plasma fibrin clot properties in atopic dermatitis: Links between thrombosis and atopy. J Thromb Thrombolysis 2010;Aug. 30(2):121–6.
8. Orita T, Tsurutani T, Izumihara A, Kajiwara K. Distal Posterior Cerebral Artery Aneurysms—three case reports. Neurol Med Chir (Tokyo) 1994;Oct. 34(10):692–6.
9. Peluzzo AM, Autieri MV. Challenging the paradigms: Anti-inflammatory interleukins and Angiogenesis. Cells 2022;Feb. 11(3):587.
10. Potter TBH, Tannous J, Vahidy FS. A contemporary review of epidemiology, risk factors, etiology, and outcomes of premature stroke. Current Atherosclerosis Reports 2022;Dec. 24(12):939–48.
11. Su VY, Chen TJ, Yeh CM, Chou KT, Hung MH, Chu SY, et al. Atopic dermatitis and risk of ischemic stroke: A nationwide population-based study. Annals of Medicine 2014;Mar. 46(2):84–9.
12. Wautier JL, Wautier MP. Vascular permeability in diseases. Int J Mol Sci 2022;Mar. 23(7):3645.
13. Zhang W, Li G, Wang X, Gao Y, Gao P, Wang B. The presence of coexisting internal carotid artery occlusion is the main associated factor of posterior cerebral artery aneurysm rupture. World Neurosurg 2025;Feb. 194:123532.
14. Zhu H, Wang Z, Yu J, Yang X, He F, Liu Z, et al. Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage. Progress in Neurobiology 2019;Jul. 178:101610.

Article information Continued

Fig. 1.

(A) Initial brain computed tomography presented diffuse subarachnoid hemorrhage. (B) The fusiform aneurysm was seen on distal P3 at parieto-occipital artery. (C) Coil embolization was performed with stent assistance and postprocedural angiogram showed the complete occlusion without any complication. (D) No abnormality was shown in the follow up angiogram.

Table 1.

Reported cerebrovascular events temporally associated with Dupilumab therapy

Author (Year) Age/Sex Underlying disease Duration of Dupilumab therapy Cerebro vascular event Proposed mechanism Management Outcome
Iwase et al. (2020) [5] 20/M Atopic dermatitis 6 months Bicerebellar ischemic stroke Possible pro-inflammatory & pro-thrombotic changes following IL-4/IL-13 pathway inhibition Dupilumab discontinuation, antiplatelet therapy Good recovery without recurrence
Present case 27/M Atopic dermatitis 2 years (48 doses) SAH due to ruptured distal PCA fusiform aneurysm Possible endothelial dysfunction, thromboinflammatory changes & vascular remodeling alterations related to chronic IL-4/IL-13 pathway inhibition Stent-assisted coil embolization & discontinuation of Dupilumab Full recovery without neurological deficit
Feng et al. (2025) [2] 96/M Bullous pemphigoid Several months Recurrent cerebral infarction/TIA Hemodynamic instability & cerebral hypoperfusion during Dupilumab therapy Medical treatment & drug discontinuation Clinical stabilization

IL, interleukine; PCA, posterior cerebral artery; SAH, subarachnoid hemorrhage; TIA, transient ischemic attack